[ADVERT]
Share Name Share Symbol Market Type Share ISIN Share Description
Hutchmed (china) Limited LSE:HCM London Ordinary Share KYG4672N1198 ORD USD0.10
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  14.00 2.58% 556.00 556.00 559.00 559.00 550.00 551.00 217,382 16:35:04
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 166.7 -138.8 -13.2 - 4,806

Hutchmed (china) Share Discussion Threads

Showing 3126 to 3150 of 3500 messages
Chat Pages: Latest  128  127  126  125  124  123  122  121  120  119  118  117  Older
DateSubjectAuthorDiscuss
24/3/2021
16:56
Just out of interest as never really given it much thought but does anyone think hcm is becoming an attractive bid target for a major player or does the fact that it's a China based company make it too difficult a proposition. Just pure speculation.
its the oxman
24/3/2021
13:35
Disposal of no-core / non-strategic asset OTC Business seems to make perfect sense and a price of 22x net profit appears good too. The aggregate amount to be received by HUTCHMED of approximately $169 million in cash represents about 22 times HBYS' adjusted net profit attributable to HUTCHMED equity holders of $7.7 million in 2020[1]. Of the proceeds, approximately $127 million is related to its shareholding in HBYS with the approximately $42 million balance related to distributions of the previously announced land compensation and prior year undistributed profits.
nerdofsteel
22/3/2021
17:54
looking very likely Hutchmed want to go for a listing in H1 so I am hopeful for news very soon. With Q1 almost over I am also looking forward to significant Sulanda and Elunate sales updates at the AGM. Savo China approval imminent too.
nerdofsteel
22/3/2021
16:38
Zzzzzz zzzz yawn
steeplejack
22/3/2021
15:34
No bounce for us it seems.
its the oxman
17/3/2021
16:51
just really hope they get on with it - I'd like to see a valuation approaching that of Innovent - similar Co's, similar pipelines, similar revs and earnings (losses) and they have an mcap of $14bn
nerdofsteel
17/3/2021
11:55
NoS, agreed - has to be more to it.
dbadvn
17/3/2021
07:26
The more recent senior management have share options with some tranches at strike prices higher than today's share price, so I would have thought there's an incentive for them to see the Company's valuation increase significantly. 689 is very interesting but not forecast to become a Blockbuster - peak sales are forecast at $189m China and $488m ROW. The Company's pipeline and prospects are so significant I can't really see how 689 could make a difference to the success of an Asian listing but maybe the latest data is so compelling the previous sales projections will be increased significantly.
nerdofsteel
17/3/2021
06:50
The company had number of ‘breakthrough’ opportunities viz, approval for fruquintinib/ and launching of Elunate/Sulanda. What exactly is the intention behind the precondition of ‘commercialisation success’ for listing at HK/ STAR? There weren’t any such preconditions before listing at London and NYSE. Is the management ‘concernedR17; with a much higher share price? Or, is a lower share price much preferred for some unknown reason?
sportii
17/3/2021
01:27
Given that there have been many successful listings in the meantime I think that the real condition CH was waiting on was the chance to announce a major breakthrough at the time of listing rather than a market condition per se. I think that 689 is it.
dbadvn
16/3/2021
16:56
thx Whatja, 689 development is certainly accelerating now..... DBADVN, I wonder what market conditions they are looking for to get a successful listing in HK on or the Star Market? There has been a general Biopharma selloff in Asia in the last few weeks but it seems to me that it will always be difficult to time exact market conditions. There are many examples of successful HK listings, even at the time Hutchmed pulled theirs in 2019 others went ahead.
nerdofsteel
16/3/2021
14:45
Best wishes NoS. Hope 689 can be of some assistance to you.....that would make HCM a better investment than Beigene.
whatja
16/3/2021
13:35
NoS . let us know what you come up with. I looked at all my past meeting notes with CH and he has never before indicated any time spans less than a year ,ever. That's why I think the "nine months comment " is significant. He has always been bullish on 689 as their ace in the hole ,and it seems to working out that way. I also like the way that HM now seem to be under promising and overdelivering commercially - its a win win strategy,
dbadvn
16/3/2021
07:45
That certainly seems likely DBADVN, I'll do more research into the trials, especially as I have a form on indolent NHL. Forecast peak sales for 689 are $109m China and $488m US/ROW.
nerdofsteel
15/3/2021
16:03
Its buried in the presentation at the end but basically it is (so far ) more effective and much lower toxicity than existing treatments and the end market is something North of $6bn and unfortunately growing. Its 100% HM also .
dbadvn
15/3/2021
15:38
I hope your right given our lowly share price, certainly seems little point in selling now. Would welcome any sketchy thoughts on 689 blockbuster potential?
its the oxman
15/3/2021
15:28
After a few days thought my view of HCM has I think become more clarified. The BioTechs that have soared in value have mostly had what is perceived to be a "Blockbuster" product - at least a good possibility thereof. HCM has never claimed to have that , and the strategy is openly to pursue low toxicity combinations . In time this will produce a reliable long term revenue stream which will justify a higher mkt cap. So far so good and it is happening. Lurking in the background is 689 which actually does have "Blockbuster" potential. I think that CH has been waiting until 689 can be shown to have real Blockbuster potential before going for the Asian listing ( "the right conditions ". And I think that this is now close to happening ! ( hence the "exciting next 9 months "). I think that the last two big investors came on board because they also see that.
dbadvn
11/3/2021
12:10
Thank you from me too DBADVN. Probably should be averaging down at this level while out of favour. Would have to sell some other better performer to fund the buy though. What is that about running your winners? At least the spread is better at the moment. Does tend to fluctuate though, which also doesn't help matters!
lauders
10/3/2021
18:55
I agree that attracting Asian investors is key here. There appears very little appetite from UK investors who have historically never understood Biopharma, especially Hutchmed. The U.S. Investors seem dis-interested too. I remain invested and see the enormous potential of the Company whilst also recognising the huge progress.
nerdofsteel
10/3/2021
18:48
NASDAQ volume today is already 1.2m against an average of 200k, looks like someone is selling a lot of stock
nerdofsteel
10/3/2021
18:21
I would need some convincing to buy this stock as a new investor.The chart is horrid.The shares have been peppered with ill timed placings on the Nasdaq,the management have a questionable faith in the attractions of the AIM market while seeming reluctant to facilitate Asiatic investor interest through an HK listing.You would think a Chinese company would want to draw on 'home' investor support.Hutchmed is the antithesis of the likes of Tiziana which really doesn't have much by way of product but markets itself very effectively.(Note that Tiziana recently left AIM and took a full LSE listing).I suppose i'll stick with Hutch because it'll be just my luck that it's inherent drug attractions ultimately overcome transitory concerns.
steeplejack
10/3/2021
15:33
DBADVN Thank you for asking the questions, the insight is v helpful Keeping the faith and hoping to get very excited later this year.
whatja
10/3/2021
15:31
Real test of faith being a hcm holder.
its the oxman
10/3/2021
15:29
Yes, very informative but what has been consistent in a month has been the almost daily bleed down. It isn't easy catching a falling very sharp knife and to buy after 25% in a month would feel just that.
fionascott1234
10/3/2021
14:31
DBADVN, many thanks for this, very useful & appreciated. Cisk
cisk
Chat Pages: Latest  128  127  126  125  124  123  122  121  120  119  118  117  Older
ADVFN Advertorial
Your Recent History
LSE
HCM
Hutchmed (..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210917 23:39:34